SGLT2抑制剂与糖尿病酮症酸中毒:来自FDA不良事件报告系统的数据
该研究基于美国FDA不良事件报告系统(FAERS)数据,分析SGLT2抑制剂相关糖尿病酮症酸中毒(DKA)报告。截至2016年第三季度,FAERS含超过2500份将SGLT2i列为可疑或合并用药的DKA报告,比例报告比(PRR)为7.9(95%CI 7.5, 8.4),1型糖尿病更高。对2014年第一季度至2016年第三季度2397份报告的详细分析显示,DKA可发生于任何年龄、体重和治疗时长,其中37例(1.54%)致命。
要点
- FAERS中SGLT2i相关DKA报告超过2500份,PRR为7.9(95%CI 7.5, 8.4)。
- 2397份详细分析显示DKA以女性为主,年龄和体重范围极宽,用药至起病时长高度可变。
- 37例(1.54%)DKA报告为致命性。
核心结论
- 基于这些报告的特征,SGLT2i相关DKA可能不限于任何特定人群或合并症亚组,且可在SGLT2i使用的任何时长发生。
研究设计与样本
- 研究首先分析截至2016年第三季度的整个公开FAERS数据库,提取报告数、背景适应症和合并用药,并计算比例报告比(PRR)和安全信号。
- 随后挖掘2014年第一季度至2016年第三季度的单个FAERS文件,获取DKA报告的详细信息。
主要发现
- FAERS数据库含超过2500份将SGLT2i列为可疑或合并用药的DKA报告。
- 在有糖尿病适应症的报告者中,含SGLT2i vs 不含SGLT2i的DKA PRR为7.9(95%CI 7.5, 8.4),1型糖尿病更高。
- 多种合并疾病在SGLT2i相关DKA报告 vs 其他药物DKA报告中患病率较低。
- 对2014年第一季度至2016年第三季度2397份SGLT2i相关DKA报告的详细分析显示女性占多数,年龄和体重范围极宽,SGLT2i治疗至DKA起病时长高度可变。
- 37例(1.54%)DKA为致命性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are indicated for the treatment of type 2 diabetes and may also improve glucose control in type 1 diabetes. In 2015, regulatory agencies warned that SGLT2i may favour diabetic ketoacidosis (DKA). We provide a detailed analysis of DKA reports in which an SGLT2i was listed among suspect or concomitant drugs in the US Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: We first analysed the entire public FAERS up to September (third quarter [Q3]) 2016 to extract the number of reports, background indications and concomitant medications, and to calculate proportional reporting ratios (PRRs) and safety signals. We then mined single FAERS files from the first quarter (Q1) of 2014 to 2016 Q3 to obtain detailed information on DKA reports. RESULTS: The FAERS database contains >2500 DKA reports in which SGLT2i are listed as suspect or concomitant drugs. The PRR of DKA in reports including vs those not including an SGLT2i and having a diabetes indication was 7.9 (95% CI 7.5, 8.4) and was higher for type 1 diabetes. Several concomitant conditions were less prevalent in DKA reports with SGLT2i vs DKA reports filed for other drugs. A detailed analysis of 2397 DKA reports for SGLT2i from 2014 Q1 to 2016 Q3 revealed a predominance of women, an extremely wide range of age and body weight, and a highly variable duration of SGLT2i treatment before onset of DKA. In 37 individuals (1.54%), DKA was fatal. CONCLUSIONS/INTERPRETATION: Based on the profile of these reports, SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation and can occur at any duration of SGLT2i use. DATA AVAILABILITY: A list of FDA reports analysed in the study is available in the figshare repository, 10.6084/m9.figshare.4903211 . Other data are available from the corresponding author on reasonable request.
引用
- Fadini GP, Bonora BM, Avogaro A, et al. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017. PMID: 28500396. doi:10.1007/s00125-017-4301-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。